|
?:authorAffiliation
|
-
[\'Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. peng.jiang@nih.gov.\', \'Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.\', \'Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China.\', \'Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.\', \'Office of the Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.\', \'XOMA Biotechnology, Emeryville, CA, USA.\', \'Ascendis Pharma, San Francisco, CA, USA.\', \'Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.\', \'Department of Health Policy and Management, School of Public Health, Yale University, New Haven, CT, USA.\', \'Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. kai_wucherpfennig@dfci.harvard.edu.\', \'Department of Immunology, Harvard Medical School, Boston, MA, USA. kai_wucherpfennig@dfci.harvard.edu.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}